Last reviewed · How we verify
A Phase 1, Dose-escalation, Open Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of the Recombinant Human Type 5 Adenovirus Vector Based Ebola Vaccine (Ad5-EBOV) in Healthy Adult Africans Aged Between 18-60 Years in China
This is a single center, open, dose-escalation phase 1 clinical trial. This study will determine the safety and side-effect profile, and immunogenicity of an investigational Ad5-EBOV vaccine in Healthy Adult Africans aged between 18-60 years in China.
Details
| Lead sponsor | First Affiliated Hospital of Zhejiang University |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 61 |
| Start date | 2015-03 |
| Completion | 2015-07 |
Conditions
- Ebola Virus Disease
Interventions
- Ad5-EBOV
Primary outcomes
- A Phase I, Open Clinical Trial to Evaluate the Adenovirus Type 5 Vector Based Ebola Virus Disease Vaccine (Ad5-EBOV) in Healthy Adult Africans in China. — From March to July, 2015
Countries
China